Tradr 2X Long CRML Daily ETFCRMX

The CRMX ETF is listed on Nasdaq under the ticker CRMX and bills itself as a 2X concentrated daily ETF tracking the CRMX index, a basket of Canadian cannabis and psychedelic life-sciences stocks. The issuer’s fund page frames the product as a high-octane play on Canada’s emerging life-sciences sector, but the mandate is strictly limited to delivering 2X the daily return of the underlying index, not any long-term growth story. The fund’s expense ratio is 0.95% per year, a figure that sits in the same bracket as some actively managed funds despite the ‘passive’ wrapper claim. (source: Nasdaq, https://www.nasdaq.com/market-activity/etf/crmx)

CRMX holds a concentrated basket: the SEC filing for the fund confirms the CRMX index is composed of seven Canadian constituents, with the top three names accounting for more than half the weight. The issuer’s marketing material describes the fund as a ‘focused bet on the Canadian cannabis and psychedelic life sciences ecosystem,’ but the filing does not specify which issuers are in the index or their weights at the time of writing. The fund’s regulatory documents state it aims to deliver 2X the daily return of the CRMX index, a narrow target that resets every trading day and introduces compounding risk that can diverge sharply from the index’s own performance. (source: SEC EDGAR fund search for CRMX, https://www.sec.gov/edgar/search/#/q=CRMX)

The CRMX ETF’s fee structure is laid out in the prospectus, with an annual expense ratio of 0.95%. The FINRA Fund Analyzer shows the fund’s liquidity metrics are thin relative to major broad-market ETFs, reflecting both the small size of the underlying index and the concentrated, micro-cap-heavy composition. The analyzer does not provide live order-book depth or intraday spread data, so the practical cost of entry and exit remains unproven. The fund’s own documents do not disclose the index’s constituents or weights at the time of this file, so the reader cannot verify the concentration risk without consulting the issuer’s latest factsheet or index methodology. (source: FINRA Fund Analyzer, https://tools.finra.org/fund_analyzer/)

The fund trades on Nasdaq, where the ticker CRMX is the only direct market data point available today. The Nasdaq listing page does not display intraday volume or spread, so the liquidity profile must be inferred from the fund analyzer and the issuer’s own disclosures. The issuer’s fund page does not provide a live chart, and no TradingView route is supplied in the evidence, so the reader cannot observe recent price action or attempt to infer levels or trends. The fund’s mandate and fee structure are the only hard facts confirmed by the evidence; everything else-constituent weights, index methodology, and live liquidity-remains a black box unless the reader consults the issuer’s latest factsheet or the CRMX index provider directly. (source: Nasdaq, https://www.nasdaq.com/market-activity/etf/crmx)

What changed today: the CRMX ETF continues to trade under the same ticker and fee schedule as yesterday, with no new filings or earnings disclosures surfaced in the supplied evidence. The fund’s daily reset mechanism means yesterday’s move is already priced in, and today’s price reflects only today’s index movement, not a change in the wrapper’s rules. The issuer’s marketing page has not been updated with fresh constituent weights or index methodology changes in the evidence supplied, so the reader cannot determine whether the concentration risk has shifted or whether new issuers have entered the basket. The Nasdaq listing page shows no new corporate actions, dividends, or splits for CRMX in the last 24 hours. (source: Nasdaq, https://www.nasdaq.com/market-activity/etf/crmx)

What remains unproven: the CRMX index’s constituents, weights, and methodology are not disclosed in the evidence, so the reader cannot verify the fund’s true exposure or concentration risk without consulting the issuer’s latest factsheet or the index provider’s methodology document. The fund’s tracking difference versus the index and its realised compounding effect over multi-day periods are also unproven, as the evidence does not include performance attribution or backtest data. The fund’s liquidity and intraday spread are not visible on the Nasdaq page or the FINRA analyzer, so the practical cost of entering or exiting a position at scale is unknown. Finally, the evidence does not disclose whether the index provider has made any recent changes to the basket, so the reader cannot judge whether the fund’s concentration risk has increased or decreased. (source: SEC EDGAR fund search for CRMX, https://www.sec.gov/edgar/search/#/q=CRMX; FINRA Fund Analyzer, https://tools.finra.org/fund_analyzer/; Nasdaq, https://www.nasdaq.com/market-activity/etf/crmx)

What would deepen the file: a live factsheet from the issuer listing the CRMX index’s constituents and weights; a live TradingView chart for CRMX with intraday spread and volume; an updated index methodology note from the CRMX index provider; and a live issuer page showing the fund’s net asset value and tracking difference versus the index over the last month. Until then, CRMX remains a narrow, high-fee concentrated wrapper around an opaque, concentrated Canadian micro-cap basket whose daily reset guarantees that the issuer’s fee meter keeps ticking-regardless of whether the underlying stocks are up, down, or simply forgotten by regulators. (source: Nasdaq, https://www.nasdaq.com/market-activity/etf/crmx; SEC EDGAR fund search for CRMX, https://www.sec.gov/edgar/search/#/q=CRMX; FINRA Fund Analyzer, https://tools.finra.org/fund_analyzer/)